PP405, a topical LDH inhibitor, has shown to stimulate hair follicle stem cell proliferation in humans with moderate hair loss. They are advancing to more detailed trials this year.
RU58841 users report mixed results, with some experiencing no benefits and others noting regrowth but potential side effects. Many prefer finasteride and minoxidil due to better-studied safety profiles.
The user experienced no improvement in hair loss with finasteride and minoxidil but had side effects. They plan to add wounding, scalp massage, vitamin K, and taurine supplements to their regimen and seek feedback on these additions.
A new human trial using an FDA-approved treatment for wound healing called Verteporfin, which may potentially be able to reverse scarring and regrow hair in that area. The trial is only lasting one month so far.
The post discusses a theory that hair regrowth after transplant is due to the angiogenesis process (new blood vessels forming), not because the transplanted hair is unaffected by DHT. The responses highlight the established belief in 'donor dominance' (the importance of the hair's origin in transplantation) and skepticism about the new theory.
Hair loss treatments, specifically 5AR inhibitors, can impact neurosteroids and sexual health. The effects of topical fin/dut on tissue-specific DHT levels are unclear.
Oral minoxidil, finasteride, and dutasteride are being used to treat hair loss, but results are limited, leading to consideration of a hair transplant. The user plans to continue medication for another year before deciding on further action.
The potential of using a specific antibody, HMI-115, as a treatment for hair loss alongside traditional treatments such as minoxidil and finasteride. The user suggests trying either a 240 mg or 30 mg dose to see if it works.
Oral minoxidil and finasteride can lead to quick hair growth, with some users noticing changes in as little as 2-3 weeks, though head hair may take longer. Many prefer oral minoxidil over topical due to convenience, and some also use ketoconazole shampoo and other topical treatments.
The user experienced significant hair growth after using oral finasteride, topical minoxidil, and microneedling weekly for a year. They initially had low libido but resolved it by taking finasteride at night.
PP405 and GT20029 are new hair loss treatments with different mechanisms from traditional options like Minoxidil and Finasteride. PP405 targets hair follicle stem cells to reactivate growth, while GT20029 works as an androgen receptor deleter, both requiring ongoing use for effectiveness.
The user experienced reduced effectiveness of minoxidil after consistent use, despite using dutasteride to maintain hair. They are considering alternatives like microneedling and exploring options like hair transplants due to dissatisfaction with current hair density.
The user experienced new hair growth after switching from oral finasteride to topical RU58841 with minoxidil and undergoing stem cell therapy. They noticed new hairs at the hairline and temples, but are unsure which treatment is responsible.
The user tried various hair loss treatments, including Maxogen-X, Dualgen15, minoxidil, finasteride, and dermarolling, but experienced limited regrowth and some side effects. They eventually switched to oral minoxidil, hoping for better results.
A user's experience of using Fin, Min and Microneedle treatments to help thicken their hair before undergoing a Hair Transplant (HT) procedure. The conversation also includes discussion about the results post-HT, including pictures.
A user shared a 3-month hair regrowth transformation using Finasteride 1mg, Minoxidil, and occasional derma rolling. Some responders are skeptical of the rapid growth, while others suggest the user might be an exceptional responder to the treatment.
Kintor Pharmaceutical's stock rise suggests potential positive news about Pyrilutamide, a topical anti-androgen. GT20029 may also compete with existing treatments like finasteride and dutasteride.
PP405 is a new hair loss treatment targeting dormant hair follicles, with ongoing trials. Some users consider stopping finasteride and minoxidil to join trials, while others doubt its effectiveness.
The conversation discusses why some people who use hard drugs have great hair, with various opinions suggesting genetics and higher estrogen levels as possible reasons. Specific treatments like Minoxidil, finasteride, and RU58841 are not mentioned.
The user has been using minoxidil and finasteride for hair loss without positive results and switched to dutasteride 1.5 months ago. They suspect seborrheic dermatitis might be affecting the effectiveness of these treatments.
The user experienced hair thinning and used Minoxidil and Finasteride over 20+ years, with periods of stopping and restarting treatment, and eventually had a hair transplant. They are considering restarting Minoxidil and Finasteride and are curious about the effectiveness and potential shedding after resuming the treatment.
A 21-year-old male with advanced hair loss (NW7) started using finasteride and minoxidil 10 months ago but hasn't seen much progress. He is pre-diabetic with stage 1 hypertension and is seeking insights on whether treating these conditions could improve hair regrowth.
A 20-year-old male is unsure how to interpret his bloodwork results and whether he should take finasteride for hair loss. His bloodwork shows borderline high levels of albumin and testosterone, and high progesterone, but normal levels of other hormones.
Actifolic RU-58841 powder and GhK-Cu peptide were tested and found to be accurate. The user is satisfied with the product's authenticity for hair loss treatment.
The user discussed switching from RU58841 with Minoxidil to Finasteride due to cost, noting better physical feelings and hair growth with RU58841. They are considering returning to RU58841 and checking DHT levels after a month.
User discusses group buy for finerenone, a third-gen mineralocorticoid antagonist for hair loss treatment. Finerenone inhibits TGFb, NOX, and ROS, and improves renal and cardiac function; topical dose should be no more than 10mg per day.
A hair restoration case involved injecting four different doses of Verteporfin into the mid scalp and using Scalp MicroPigmentation (SMP) around the extraction areas. Photos were taken and an update will be shared soon.
A South Korean company, Therazyne, has developed a promising hair loss treatment using a WNT chain surrogate that binds to Frizzled 7, with human follicle testing expected soon. Current treatments like minoxidil and finasteride are not seen as cures, and while optimism exists for future solutions like PP405, approval processes are lengthy.